{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:39:16Z","timestamp":1787243956166,"version":"build-2736575974"},"reference-count":212,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm of chronic myeloid leukemia (CML), leading to a dramatic improvement of the outcome of CML patients, who now have a nearly normal life expectancy and, in some selected cases, the possibility of aiming for the more ambitious goal of treatment-free remission (TFR). However, the minority of patients who fail treatment and progress from chronic phase (CP) to accelerated phase (AP) and blast phase (BP) still have a relatively poor prognosis. The identification of predictive elements enabling a prompt recognition of patients at higher risk of progression still remains among the priorities in the field of CML management. Currently, the baseline risk is assessed using simple clinical and hematologic parameters, other than evaluating the presence of additional chromosomal abnormalities (ACAs), especially those at \u201chigh-risk\u201d. Beyond the onset, a re-evaluation of the risk status is mandatory, monitoring the response to TKI treatment. Moreover, novel critical insights are emerging into the role of genomic factors, present at diagnosis or evolving on therapy. This review presents the current knowledge regarding prognostic factors in CML and their potential role for an improved risk classification and a subsequent enhancement of therapeutic decisions and disease management.<\/jats:p>","DOI":"10.3390\/cells12131703","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T02:23:09Z","timestamp":1687746189000},"page":"1703","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights"],"prefix":"10.3390","volume":"12","author":[{"given":"Miriam","family":"Iezza","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Cortesi","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Ottaviani","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Mancini","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Venturi","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Monaldi","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Santis","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Testoni","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Universit\u00e0 di Bologna, 40138 Bologna, Italy"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Universit\u00e0 di Bologna, 40138 Bologna, Italy"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Universit\u00e0 di Bologna, 40138 Bologna, Italy"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of C-Abl Oncogene Correlates with the Presence of a Philadelphia Chromosome In chronic myelocytic Leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The Molecular Biology of Chronic Myeloid Leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible Chronic Phase of Myeloid Leukemia with Expansion of Hematopoietic Stem Cells in a Transgenic Model of BCR-ABL Leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the Stem of Chronic Myeloid Leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_10","first-page":"935","article-title":"Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: Which, When, for Whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11899-016-0304-7","article-title":"Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression from Chronic Phase","volume":"11","author":"Mukherjee","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and Efficacy of Imatinib in CML over a Period of 10 Years: Data from the Randomized CML-Study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-Term Outcomes with Frontline Nilotinib versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 10-Year Analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of Imatinib as First-Line Treatment of Chronic Myeloid Leukemia: 10-Year Survival Results of the Randomized CML Study IV and Impact of Non-CML Determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing Chronic Myeloid Leukemia for Treatment-Free Remission: A Proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv."},{"key":"ref_20","unstructured":"(2023, May 03). National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml_blocks.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I Treat CML Blast Crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of Chronic Myeloid Leukemia in Advanced Phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_23","unstructured":"(2023, February 17). Cancer Stat Facts: Leukemia\u2013Chronic Myeloid Leukemia (CML), Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00007611-198710000-00007","article-title":"Old Age: A Sign of Poor Prognosis in Patients with Chronic Myelogenous Leukemia","volume":"80","author":"Kantarjian","year":"1987","journal-title":"South. Med. J."},{"key":"ref_25","first-page":"1517","article-title":"An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/sj.leu.2403042","article-title":"Chronic Myeloid Leukemia in the Elderly: Long-Term Results from Randomized Trials with Interferon \u03b1","volume":"17","author":"Berger","year":"2003","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of Age on Prognosis with Imatinib Mesylate Therapy for Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of Age on the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clml.2021.04.005","article-title":"Efficacy and Safety of Imatinib Treatment in Elderly Patients with Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience","volume":"21","author":"Bayraktar","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.critrevonc.2012.01.001","article-title":"Tyrosine Kinase Inhibitors for Elderly Chronic Myeloid Leukemia Patients: A Systematic Review of Efficacy and Safety Data","volume":"84","author":"Breccia","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00432-017-2402-x","article-title":"Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase: ENEST1st Subanalysis","volume":"143","author":"Giles","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline Imatinib Treatment of Chronic Myeloid Leukemia: No Impact of Age on Outcome, a Survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among Young Adults, Adults and Elderly Chronic Myeloid Leukemia Patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger Patients with Chronic Myeloid Leukemia Do Well in Spite of Poor Prognostic Indicators: Results from the Randomized CML Study IV","volume":"93","author":"Kalmanti","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of Outcomes in Adolescents and Young Adults with Chronic Myelogenous Leukemia Treated with Upfront Tyrosine Kinase Inhibitor Therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of Multimorbidity and Implications for Health Care, Research, and Medical Education: A Cross-Sectional Study","volume":"380","author":"Guthrie","year":"2012","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of Cardiovascular and Arteriothrombotic Adverse Events in Chronic-Phase CML Patients after Frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/hematology.2020006911","article-title":"Handling challenging questions in the management of CML. How to Manage CML Patients with Comorbidities","volume":"1","author":"Cortes","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of Comorbidities on Overall Survival in Patients with Chronic Myeloid Leukemia: Results of the Randomized CML Study IV","volume":"126","author":"Hehlmann","year":"2015","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"739171","DOI":"10.3389\/fonc.2021.739171","article-title":"Prognostic Factors for Overall Survival in Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network","volume":"11","author":"Specchia","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-016-2074-3","article-title":"Charlson Comorbidity Index Predicts Poor Outcome in CML Patients Treated with Tyrosine Kinase Inhibitor","volume":"104","author":"Uemura","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1111\/cas.14580","article-title":"Prognostic Effect of Comorbidities in Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor","volume":"111","author":"Ono","year":"2020","journal-title":"Cancer Sci"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2021-154497","article-title":"63rd ASH Annual Meeting Abstracts POSTER ABSTRACTS 632.CHRONIC MYELOID LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL. The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors","volume":"138","author":"Kim","year":"2021","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic Discrimination in \u201cGood-Risk\u201d Chronic Granulocytic Leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A New Prognostic Score for Survival of Patients with Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting Complete Cytogenetic Response and Subsequent Progression-Free Survival in 2060 Patients with CML on Imatinib Treatment: The EUTOS Score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of Long-Term Survival Considering Disease-Specific Death in Patients with Chronic Myeloid Leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41375-020-0931-9","article-title":"The EUTOS Long-Term Survival (ELTS) Score Is Superior to the Sokal Score for Predicting Survival in Chronic Myeloid Leukemia","volume":"34","author":"Pfirrmann","year":"2020","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41375-018-0136-7","article-title":"Validation of the EUTOS Long-Term Survival Score in a Recent Independent Cohort of \u201cReal World\u201d CML Patients","volume":"32","author":"Geelen","year":"2018","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"E661","DOI":"10.1002\/ajh.24913","article-title":"The Eutos Long-Term Survival Score Accurately Predicts the Risk of Death in Chronic Myeloid Leukaemia Patients Treated Outside of Clinical Trials","volume":"92","author":"Molica","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","article-title":"Is the Sokal or EUTOS Long-Term Survival (ELTS) Score a Better Predictor of Responses and Outcomes in Persons with Chronic Myeloid Leukemia Receiving Tyrosine-Kinase Inhibitors?","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2018-99-117409","article-title":"The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients","volume":"132","author":"Castagnetti","year":"2018","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e27827","DOI":"10.1002\/pbc.27827","article-title":"Management of Chronic Myeloid Leukemia in Children and Adolescents: Recommendations from the Children\u2019s Oncology Group CML Working Group","volume":"66","author":"Athale","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc799","article-title":"Oncogenic Tyrosine Kinases and the DNA-Damage Response","volume":"2","author":"Skorski","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL Oncogenic Kinase Promotes Unfaithful Repair of the Reactive Oxygen Species-Dependent DNA Double-Strand Breaks","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"key":"ref_58","first-page":"260","article-title":"Chronic Myeloid Leukemia in Chronic Phase Responding to Imatinib: The Occurrence of Additional Cytogenetic Abnormalities Predicts Disease Progression","volume":"88","author":"Marktel","year":"2003","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional Chromosomal Abnormalities in Philadelphia-Positive Clone: Adverse Prognostic Influence on Frontline Imatinib Therapy: A GIMEMA Working Party on CML Analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML: Long-Term Observation of 1151 Patients from the Randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk Stratification of Chromosomal Abnormalities in Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-4608(85)90041-X","article-title":"Karyotypic Evolution in Ph-Positive Chronic Myeloid Leukemia in Relation to Management and Disease Progression","volume":"18","author":"Swolin","year":"1985","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_63","first-page":"628","article-title":"The Relationship between Secondary Chromosomal Abnormalities and Blast Transformation in Chronic Myelogenous Leukemia","volume":"9","author":"Anastasi","year":"1995","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V66.6.1326.1326","article-title":"Chronic Myelogenous Leukemia: A Multivariate Analysis of the Associations of Patient Characteristics and Therapy with Survival","volume":"66","author":"Kantarjian","year":"1985","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic Significance of Cytogenetic Clonal Evolution in Patients with Chronic Myelogenous Leukemia on Imatinib Mesylate Therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ijc.2910180105","article-title":"Non-Random Karyotypic Evolution in Chronic Myeloid Leukemia","volume":"18","author":"Mitelman","year":"1976","journal-title":"Int. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10428199309047856","article-title":"The Cytogenetic Scenario of Chronic Myeloid Leukemia","volume":"11","author":"Mitelman","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic Significance of Additional Cytogenetic Abnormalities at Diagnosis of Philadelphia Chromosome-Positive Chronic Granulocytic Leukemia","volume":"72","author":"Sokal","year":"1988","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.1996.14.1.196","article-title":"Significance of Cytogenetic Clonal Evolution in Chronic Myelogenous Leukemia","volume":"14","author":"Majlis","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Farag, S., Ruppert, A., Mr\u00f3zek, K., Carroll, A., Pettenati, M., Le Beau, M., Peterson, B., Powell, B., Ozer, H., and Silver, R. (2004). Prognostic Significance of Additional Cytogenetic Abnormalities in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Treated with Interferon-\u03b1: A Cancer and Leukemia Group B Study. Int. J. Oncol.","DOI":"10.3892\/ijo.25.1.143"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of Additional Chromosome Aberrations in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic Significance of Additional Chromosomal Abnormalities at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of Chronic Myeloid Leukemia in the Imatinib Era","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic Myeloid Leukemia: Mechanisms of Blastic Transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics-Based Risk Prediction of Blastic Transformation of Chronic Myeloid Leukemia in the Era of TKI Therapy","volume":"1","author":"Gong","year":"2017","journal-title":"Blood Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","article-title":"Additional Chromosomal Abnormalities at Chronic Myeloid Leukemia Diagnosis Predict an Increased Risk of Progression","volume":"5","author":"Clark","year":"2021","journal-title":"Blood Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-Risk Additional Chromosomal Abnormalities at Low Blast Counts Herald Death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of Unbalanced Minor Route versus Major Route Karyotypes at Diagnosis on Prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of Imatinib Mesylate Therapy in Chronic Myelogenous Leukaemia with Variant Philadelphia Chromosome","volume":"125","author":"Kantarjian","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia Translocations: Molecular-Cytogenetic Characterization and Prognostic Influence on Frontline Imatinib Therapy, a GIMEMA Working Party on CML Analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The Diversity of BCR-ABL Fusion Proteins and Their Relationship to Leukemia Phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular Biology of Bcr-Abl1-Positive Chronic Myeloid Leukemia","volume":"113","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","article-title":"A Multiplex PCR for Improved Detection of Typical and Atypical BCR-ABL Fusion Transcripts","volume":"32","author":"Burmeister","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.V78.5.1155.1155","article-title":"Does the Breakpoint within the Major Breakpoint Cluster Region (M-Bcr) Influence the Duration of the Chronic Phase in Chronic Myeloid Leukemia? An Analytical Comparison of Current Literature [See Comments]","volume":"78","author":"Mills","year":"1991","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2141.1995.tb08362.x","article-title":"Analysis of Molecular Breakpoint and M-RNA Transcripts in a Prospective Randomized Trial of Interferon in Chronic Myeloid Leukaemia: No Correlation with Clinical Features, Cytogenetic Response, Duration of Chronic Phase, or Survival","volume":"89","author":"Shepherd","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_86","unstructured":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1995). Chronic Myeloid Leukemia, BCR\/ABL Transcript, Response to Alpha-Interferon and Survival. Leukemia, 9, 1648\u20131652."},{"key":"ref_87","first-page":"210","article-title":"Association of the Responsiveness to Interferon Therapy with the Bcr\/Abl Splicing Pattern in Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","volume":"80","author":"Lee","year":"1992","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/cncr.31408","article-title":"The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The Proportion of Different BCR-ABL1 Transcript Types in Chronic Myeloid Leukemia. An International Overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic Myeloid Leukemia Patients with the E13a2 BCR-ABL Fusion Transcript Have Inferior Responses to Imatinib Compared to Patients with the E14a2 Transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase CML Treated with Tyrosine Kinase Inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"ref_92","first-page":"BR193-7","article-title":"Relationship of the BCR Gene Breakpoint and the Type of BCR\/ABL Transcript to Clinical Course, Prognostic Indexes and Survival in Patients with Chronic Myeloid Leukemia","volume":"8","author":"Prejzner","year":"2002","journal-title":"Med. Sci. Monit."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 Transcript Type Influences Response and Outcome in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No Influence of BCR-ABL1 Transcript Types E13a2 and E14a2 on Long-Term Survival: Results in 1494 Patients with Chronic Myeloid Leukemia Treated with Imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clml.2017.06.009","article-title":"Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib","volume":"17","author":"Pagnano","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ejh.12597","article-title":"Gender and BCR-ABL Transcript Type Are Correlated with Molecular Response to Imatinib Treatment in Patients with Chronic Myeloid Leukemia","volume":"96","author":"Lin","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood-2018-99-114036","article-title":"B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase\u2014Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line","volume":"132","author":"Miranda","year":"2018","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.18632\/oncotarget.23691","article-title":"Prognostic Factors Associated with a Stable MR4.5 Achievement in Chronic Myeloid Leukemia Patients Treated with Imatinib","volume":"9","author":"Breccia","year":"2018","journal-title":"Oncotarget"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/0019-509X.176741","article-title":"Simple Multiplex RT-PCR for Identifying Common Fusion BCR-ABL Transcript Types and Evaluation of Molecular Response of the A2b2 and A2b3 Transcripts to Imatinib Resistance in North Indian Chronic Myeloid Leukemia Patients","volume":"52","author":"Mir","year":"2015","journal-title":"Indian J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.gene.2017.06.018","article-title":"Impact of the BCR\u2014ABL1 Fusion Transcripts on Different Responses to Imatinib and Disease Recurrence in Iranian Patients with Chronic Myeloid Leukemia","volume":"627","author":"Rostami","year":"2017","journal-title":"Gene"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Marc\u00e9, S., Xicoy, B., Garc\u00eda, O., Cabez\u00f3n, M., Estrada, N., V\u00e9lez, P., Boqu\u00e9, C., Sag\u00fc\u00e9s, M., Angona, A., and Teruel-Montoya, R. (2021). Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143146"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Greenfield, G., McMullan, R., Robson, N., McGimpsey, J., Catherwood, M., and McMullin, M.F. (2019). Response to Imatinib Therapy Is Inferior for E13a2 BCR-ABL1 Transcript Type in Comparison to E14a2 Transcript Type in Chronic Myeloid Leukaemia. BMC Hematol., 19.","DOI":"10.1186\/s12878-019-0139-2"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/blood.V110.11.1047.1047","article-title":"Better Molecular Response to Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the B3a2 Transcript Compared to B2a2","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V126.23.597.597","article-title":"Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC [Abstract]","volume":"126","author":"Bonifacio","year":"2015","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct Characteristics of E13a2 versus E14a2 BCR-ABL1 Driven Chronic Myeloid Leukemia under First-Line Therapy with Imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref_106","first-page":"58","article-title":"Impact of the Major BCR-ABL1 Transcript Type on Clinical and Biological Parameters and Molecular Response in Patients with Chronic Myeloid Leukemia","volume":"15","author":"Nachi","year":"2020","journal-title":"Hematol. Oncol. Stem. Cell Ther."},{"key":"ref_107","first-page":"219","article-title":"Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/cncr.31187","article-title":"Prediction for Sustained Deep Molecular Response of BCR-ABL1 Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase","volume":"124","author":"Sasaki","year":"2018","journal-title":"Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","article-title":"The E13a2 BCR-ABL Transcript Negatively Affects Sustained Deep Molecular Response and the Achievement of Treatment-free Remission in Patients with Chronic Myeloid Leukemia Who Receive Tyrosine Kinase Inhibitors","volume":"125","author":"Farina","year":"2019","journal-title":"Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood-2018-99-111083","article-title":"The E13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort","volume":"132","author":"Shanmuganathan","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1111\/cas.15501","article-title":"Comparison of Molecular Responses and Outcomes between BCR::ABL1 E14a2 and E13a2 Transcripts in Chronic Myeloid Leukemia","volume":"113","author":"Su","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.18632\/oncotarget.27652","article-title":"Influence of Major BCR-ABL1 Transcript Subtype on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated Frontline with Nilotinib","volume":"11","author":"Genthon","year":"2020","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1182\/blood.V128.22.3070.3070","article-title":"Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib","volume":"128","author":"Castagnetti","year":"2016","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"107327482110384","DOI":"10.1177\/10732748211038429","article-title":"Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project","volume":"28","author":"Abdulla","year":"2021","journal-title":"Cancer Control."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood.V120.21.1680.1680","article-title":"The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib","volume":"120","author":"Castagnetti","year":"2012","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood.V122.21.2727.2727","article-title":"BCR-ABL Fusion Transcripts In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center","volume":"122","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic Myeloid Leukemia (CML) with P190BCR-ABL: Analysis of Characteristics, Outcomes, and Prognostic Significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.2013.092882","article-title":"Clinical Activity of Ponatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with E1a2 Transcripts","volume":"98","author":"Jain","year":"2013","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.13184","article-title":"Long-Term Outcome of Chronic Myeloid Leukaemia Patients with P210 and P190 Co-Expression at Baseline","volume":"169","author":"Molica","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","article-title":"Chronic Myeloid Leukemia: The Concepts of Resistance and Persistence and the Relationship with the BCR-ABL1 Transcript Type","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3324\/haematol.2018.189787","article-title":"BCR-ABL1 Genomic DNA PCR Response Kinetics during First-Line Imatinib Treatment of Chronic Myeloid Leukemia","volume":"103","author":"Pagani","year":"2018","journal-title":"Haematologica"},{"key":"ref_122","first-page":"1498","article-title":"HLA Class II-Restricted Antigen Presentation of Endogenous BCR-ABL Fusion Protein by Chronic Myelogenous Leukemia-Derived Dendritic Cells to CD4+ T Lymphocytes","volume":"96 Pt I","author":"Yasukawa","year":"2000","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bjh.18046","article-title":"BCR::ABL1 Transcripts and Clinical Outcome\u2014Interrogating the Technique","volume":"197","author":"Branford","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-022-01612-2","article-title":"Impact of BCR::ABL1 Transcript Type on RT-QPCR Amplification Performance and Molecular Response to Therapy","volume":"36","author":"Salmon","year":"2022","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.13238","article-title":"Variant-specific Discrepancy When Quantitating BCR-ABL1 E13a2 and E14a2 Transcripts Using the Europe Against Cancer QPCR Assay","volume":"103","author":"Kjaer","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.18026","article-title":"Assessment of Quantitative Polymerase Chain Reaction for BCR\u2013ABL1 Transcripts in Chronic Myeloid Leukaemia: Are Improved Outcomes in Patients with E14a2 Transcripts an Artefact of Technology?","volume":"197","author":"Dominy","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-009-0822-7","article-title":"Response to Imatinib Mesylate in Chronic Myeloid Leukemia Patients with Variant BCR-ABL Fusion Transcripts","volume":"89","author":"Sharma","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4238\/vol7-4gmr485","article-title":"Analysis and Comparison of Clinicohematological Parameters and Molecular and Cytogenetic Response of Two Bcr\/Abl Fusion Transcripts","volume":"7","author":"Polampalli","year":"2008","journal-title":"Genet. Mol. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V58.1.158.158","article-title":"Evidence for a Multistep Pathogenesis of Chronic Myelogenous Leukemia","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1038\/leu.2008.231","article-title":"BCR-ABL1-Positive CML and BCR-ABL1-Negative Chronic Myeloproliferative Disorders: Some Common and Contrasting Features","volume":"22","author":"Cross","year":"2008","journal-title":"Leukemia"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/10428194.2021.1894652","article-title":"Mutational Landscape of Chronic Myeloid Leukemia: More than a Single Oncogene Leukemia","volume":"62","author":"Kankainen","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the Foundation for Genomically-Based Risk Assessment in Chronic Myeloid Leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"101194","DOI":"10.1016\/j.beha.2020.101194","article-title":"CML\u2014Not Only BCR-ABL1 Matters","volume":"33","author":"Rinke","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent Somatic Mutations in Epigenetic Regulators in Newly Diagnosed Chronic Myeloid Leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of Somatic Mutation Dynamics in Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitor Therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation Accumulation in Cancer Genes Relates to Nonoptimal Outcome in Chronic Myeloid Leukemia","volume":"4","author":"Awad","year":"2020","journal-title":"Blood Adv."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-Defined Clonal Evolution in Patients with Chronic Myeloid Leukemia Independent of the BCR-ABL Status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic Variants in Epigenetic Modifiers Can Predict Failure of Response to Imatinib but Not to Inhibitors Second-Generation Tyrosine Kinase","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal Hematopoiesis of Indeterminate Potential and Its Distinction from Myelodysplastic Syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 Mutations in Children and Young Adults with Chronic Myeloid Leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0609.2012.01755.x","article-title":"Absence of DNMT3A Gene Mutation in Chronic Myeloid Leukemia Patients in Blast Crisis","volume":"88","author":"Li","year":"2012","journal-title":"Eur. J. Haematol"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2016-11-746842","article-title":"Antecedent CHIP in CML?","volume":"129","author":"Walter","year":"2017","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"E623","DOI":"10.1002\/ajh.24865","article-title":"Somatic Mutations Identified at Diagnosis by Exome Sequencing Can Predict Response to Imatinib in Chronic Phase Chronic Myeloid Leukemia (CML) Patients","volume":"92","author":"Mologni","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic Impact of ASXL1 Mutations in Chronic Phase Chronic Myeloid Leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Chronic Myeloid Leukemia","volume":"36","author":"Rinke","year":"2022","journal-title":"Leukemia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12288-019-01213-7","article-title":"Re-Defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma","volume":"36","author":"Jain","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00277-015-2327-x","article-title":"Response-Related Predictors of Survival in CML","volume":"94","author":"Hanfstein","year":"2015","journal-title":"Ann Hematol"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML Patients Responding to Treatment with Tyrosine Kinase Inhibitors: Review and Recommendations for Harmonizing Current Methodology for Detecting BCR-ABL Transcripts and Kinase Domain Mutations and for Expressing Results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early Molecular and Cytogenetic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early Molecular Response Predicts Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Frontline Nilotinib or Imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive Value of Early Molecular Response in Patients with Chronic Myeloid Leukemia Treated with First-Line Dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of Early BCR-ABL Transcript Elimination as an Optimized Predictor of Outcome in Chronic Myeloid Leukemia (CML) Patients in Chronic Phase on Treatment with Imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for Patients with CML and >10% BCR-ABL1 after 3 Months of Imatinib Depends on the Rate of BCR-ABL1 Decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11899-017-0375-0","article-title":"The Role of Early Molecular Response in the Management of Chronic Phase CML","volume":"12","author":"Harrington","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000524284","article-title":"Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis","volume":"45","author":"Kohlbrenner","year":"2022","journal-title":"Oncol. Res. Treat."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00277-019-03706-x","article-title":"Ten-Year Outcome of Chronic-Phase Chronic Myeloid Leukemia Patients Treated with Imatinib in Real Life","volume":"98","author":"Molica","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.15042","article-title":"Nilotinib after Imatinib First-Line: A Real-Life Longitudinal Cohort of Patients with Chronic Myeloid Leukaemia in Chronic Phase","volume":"180","author":"Gardembas","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1002\/cam4.3071","article-title":"How Many Chronic Myeloid Leukemia Patients Who Started a Frontline Second-generation Tyrosine Kinase Inhibitor Have to Switch to a Second-line Treatment? A Retrospective Analysis from the Monitoring Registries of the Italian Medicines Agency (AIFA)","volume":"9","author":"Breccia","year":"2020","journal-title":"Cancer Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clml.2013.02.025","article-title":"Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-Line Therapy for Patients With Chronic Myeloid Leukemia","volume":"13","author":"Eghtedar","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e2019025","DOI":"10.4084\/mjhid.2019.025","article-title":"Treatment patterns in patients with chronic-phase chronic myeloid leukaemia in routine clinical practice: The simplicity italian population","volume":"11","author":"Abruzzese","year":"2019","journal-title":"Mediterr. J. Hematol. Infect Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"14219","DOI":"10.18632\/oncotarget.24478","article-title":"Excellent Outcomes of 2G-TKI Therapy after Imatinib Failure in Chronic Phase CML Patients","volume":"9","author":"Tiribelli","year":"2018","journal-title":"Oncotarget"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final Results from the BFORE Trial","volume":"36","author":"Cortes","year":"2022","journal-title":"Leukemia"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00277-021-04477-0","article-title":"Real-Life Comparison of Nilotinib versus Dasatinib as Second-Line Therapy in Chronic Phase Chronic Myeloid Leukemia Patients","volume":"100","author":"Scalzulli","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-Line Therapy for Chronic Myeloid Leukemia: Current Status and Future Directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome\u2013Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-10-383000","article-title":"Responses to Second-Line Tyrosine Kinase Inhibitors Are Durable: An Intention-to-Treat Analysis in Chronic Myeloid Leukemia Patients","volume":"119","author":"Milojkovic","year":"2012","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Stein, A.M., Martinelli, G., Hughes, T.P., M\u00fcller, M.C., Beppu, L., Gottardi, E., Branford, S., Soverini, S., Woodman, R.C., and Hochhaus, A. (2013). Rapid Initial Decline in BCR-ABL1 Is Associated with Superior Responses to Second-Line Nilotinib in Patients with Chronic-Phase Chronic Myeloid Leukemia. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-173"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in Imatinib-Resistant or Imatinib-Intolerant Patients with Chronic Myeloid Leukemia in Chronic Phase: 48-Month Follow-up Results of a Phase II Study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","article-title":"Expert Opinion\u2014Management of Chronic Myeloid Leukemia after Resistance to Second-Generation Tyrosine Kinase Inhibitors","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early Prediction of Success or Failure of Treatment with Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The Significance of Myelosuppression during Therapy with Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia in Chronic Phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.leu.2402996","article-title":"Prognostic Factors for Patients with Chronic Myeloid Leukaemia in Chronic Phase Treated with Imatinib Mesylate after Failure of Interferon Alfa","volume":"17","author":"Marin","year":"2003","journal-title":"Leukemia"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12288-010-0048-9","article-title":"Total Leukocyte Counts and the Requirement of Dose Reduction Due to Cytopenias as Prognostic Indicators Affecting Response to Imatinib in Chronic Myeloid Leukemia","volume":"27","author":"Tripathi","year":"2011","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ajh.22020","article-title":"Hammersmith Score Application Identifies Chronic Myeloid Leukemia Patients with Poor Prognosis before Treatment with Second-Generation Tyrosine Kinase Inhibitors","volume":"86","author":"Breccia","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V122.21.383.383","article-title":"Prediction of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value of The Hammersmith Prediction Score","volume":"122","author":"Nicolini","year":"2013","journal-title":"Blood"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 Kinase Domain-Mediated Resistance in Chronic Myeloid Leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL Kinase Domain Mutation Analysis in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Recommendations from an Expert Panel on Behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of Kinase Domain Mutations in Patients with Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL Mutations in Patients with CML Treated with Imatinib Is Virtually Always Accompanied by Clinical Resistance, and Mutations in the ATP Phosphate-Binding Loop (P-Loop) Are Associated with a Poor Prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1002\/cam4.2410","article-title":"Incidence and Outcome of BCR-ABL Mutated Chronic Myeloid Leukemia Patients Who Failed to Tyrosine Kinase Inhibitors","volume":"8","author":"Etienne","year":"2019","journal-title":"Cancer Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-Positive Patients Who Already Harbor Imatinib-Resistant Bcr-Abl Kinase Domain Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Second- or Third-Line Tyrosine Kinase Inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia after Sequential Treatment with Multiple Tyrosine Kinase Inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood-2011-08-375535","article-title":"Poor Response to Second-Line Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Multiple Low-Level Mutations, Irrespective of Their Resistance Profile","volume":"119","author":"Parker","year":"2012","journal-title":"Blood"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2015-09-666214","article-title":"The Impact of Multiple Low-Level BCR-ABL1 Mutations on Response to Ponatinib","volume":"127","author":"Parker","year":"2016","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.leukres.2019.01.011","article-title":"Compound Mutations in CML\u2014Imaginary Bogeyman or Real Arch-Nemesis?","volume":"81","author":"Yeung","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective Assessment of NGS-Detectable Mutations in CML Patients with Nonoptimal Response: The NEXT-in-CML Study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of Low-Level BCR-ABL1 Kinase Domain Mutations Identified by next-Generation Sequencing in Patients with Chronic Myeloid Leukaemia: A Population-Based Study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A Deep-Sequencing Study of Chronic Myeloid Leukemia Patients in Blast Crisis (BC-CML) Detects Mutations in 76.9% of Cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative Genomic Analysis Reveals Cancer-Associated Mutations at Diagnosis of CML in Patients with High-Risk Disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/s41375-022-01681-3","article-title":"Impact of Emerging ACA on Survival in Chronic Myeloid Leukemia (CML)","volume":"36","author":"Hehlmann","year":"2022","journal-title":"Leukemia"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/leu.2015.96","article-title":"Impact of Trisomy 8 on Treatment Response and Survival of Patients with Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors","volume":"29","author":"Wang","year":"2015","journal-title":"Leukemia"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and Prognostic Significance of 3q26.2 and Other Chromosome 3 Abnormalities in CML in the Era of Tyrosine Kinase Inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","article-title":"First-Line Imatinib Mesylate in Patients with Newly Diagnosed Accelerated Phase-Chronic Myeloid Leukemia","volume":"26","author":"Rea","year":"2012","journal-title":"Leukemia"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/leu.2016.231","article-title":"Cytogenetic Landscape and Impact in Blast Phase of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood-2017-09-804054","article-title":"Prognostic Relevance of CCAs\/Ph\u2212 in CML Settled","volume":"130","author":"Hehlmann","year":"2017","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal Chromosomal Abnormalities Appearing in Philadelphia Chromosome-Negative Metaphases during CML Treatment","volume":"130","author":"Issa","year":"2017","journal-title":"Blood"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why Do Chronic Myelogenous Leukemia Stem Cells Survive Allogeneic Stem Cell Transplantation or Imatinib: Does It Really Matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.beha.2009.08.001","article-title":"Treatment Strategies for CML","volume":"22","author":"Goldman","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11899-022-00683-3","article-title":"CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions","volume":"17","author":"Scalzulli","year":"2022","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"e2020062","DOI":"10.4084\/mjhid.2020.062","article-title":"Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia","volume":"12","author":"Molica","year":"2020","journal-title":"Mediterr. J. Hematol. Infect Dis."},{"key":"ref_206","unstructured":"(2023, March 12). CML-1: Understanding the Clonal Hierarchy in Chronic Myeloid Leukemia to Help Improve Patient Outcomes. Available online: https:\/\/www.harmony-alliance.eu\/projects\/research-project\/cml-understanding-the-clonal-hierarchy-in-chronic-myeloid-leukemia-to-help-improve-patient-outcomes-1655723411."},{"key":"ref_207","first-page":"1619","article-title":"Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy","volume":"130","author":"Hadzijusufovic","year":"2017","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib Efficacy and Safety in Philadelphia Chromosome\u2013Positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"106734","DOI":"10.1016\/j.leukres.2021.106734","article-title":"No Margin for Non-Adherence: Probabilistic Kaplan-Meier Modeling of Imatinib Non-Adherence and Treatment Response in CML (ADAGIO Study)","volume":"111","author":"MacDonald","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.japh.2017.01.004","article-title":"Medication Adherence, Molecular Monitoring, and Clinical Outcomes in Patients with Chronic Myelogenous Leukemia in a Large HMO","volume":"57","author":"Haque","year":"2017","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/PPA.S269355","article-title":"Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review","volume":"15","author":"Tan","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3904\/kjim.2021.158","article-title":"Survival Impact of Adherence to Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J. Intern. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/13\/1703\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:59:19Z","timestamp":1760126359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/13\/1703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":212,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cells12131703"],"URL":"https:\/\/doi.org\/10.3390\/cells12131703","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]}}}